210 related articles for article (PubMed ID: 2045206)
1. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
Tanaka J; Teicher BA; Herman TS; Holden SA; Dezube B; Frei E
Int J Cancer; 1991 Jun; 48(4):631-7. PubMed ID: 2045206
[TBL] [Abstract][Full Text] [Related]
2. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
Teicher BA; Herman TS; Tanaka J; Dezube B; Pardee A; Frei E
Cancer Chemother Pharmacol; 1991; 28(1):45-50. PubMed ID: 1904012
[TBL] [Abstract][Full Text] [Related]
3. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
[TBL] [Abstract][Full Text] [Related]
4. Modulation of alkylating agents by lonidamine in vivo.
Teicher BA; Holden SA; Herman TS; Frei E
Semin Oncol; 1991 Apr; 18(2 Suppl 4):7-10. PubMed ID: 1903216
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Holden SA; Herman TS; Epelbaum R; Pardee AB; Dezube B
Anticancer Res; 1991; 11(4):1555-60. PubMed ID: 1746913
[TBL] [Abstract][Full Text] [Related]
6. Combination of etanidazole with cyclophosphamide and platinum complexes.
Teicher BA; Herman TS; Shulman L; Bubley G; Coleman CN; Frei E
Cancer Chemother Pharmacol; 1991; 28(3):153-8. PubMed ID: 1830248
[TBL] [Abstract][Full Text] [Related]
7. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
Teicher BA; Bernal SD; Holden SA; Cathcart KN
Cancer Chemother Pharmacol; 1988; 21(4):281-5. PubMed ID: 3131032
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
[TBL] [Abstract][Full Text] [Related]
9. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
10. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
Rosbe KW; Brann TW; Holden SA; Teicher BA; Frei E
Cancer Chemother Pharmacol; 1989; 25(1):32-6. PubMed ID: 2590999
[TBL] [Abstract][Full Text] [Related]
11. Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
Schwartz GN; Teicher BA; Eder JP; Korbut T; Holden SA; Ara G; Herman TS
Cancer Chemother Pharmacol; 1993; 32(6):455-62. PubMed ID: 8258194
[TBL] [Abstract][Full Text] [Related]
12. A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents.
Teicher BA; Holden SA; Ara G; Ha CS; Herman TS; Northey D
J Cancer Res Clin Oncol; 1992; 118(7):509-14. PubMed ID: 1624542
[TBL] [Abstract][Full Text] [Related]
13. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
Siemann DW; Beyers KL
Br J Cancer; 1993 Dec; 68(6):1071-9. PubMed ID: 8260357
[TBL] [Abstract][Full Text] [Related]
14. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma.
Teicher BA; Holden SA; al-Achi A; Herman TS
Cancer Res; 1990 Jun; 50(11):3339-44. PubMed ID: 2334928
[TBL] [Abstract][Full Text] [Related]
15. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
[TBL] [Abstract][Full Text] [Related]
16. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents.
Eder JP; Teicher BA; Holden SA; Cathcart KN; Schnipper LE; Frei E
Cancer Res; 1989 Feb; 49(3):595-8. PubMed ID: 2910481
[TBL] [Abstract][Full Text] [Related]
17. Influence of scheduling on two-drug combinations of alkylating agents in vivo.
Teicher BA; Holden SA; Jones SM; Eder JP; Herman TS
Cancer Chemother Pharmacol; 1989; 25(3):161-6. PubMed ID: 2513139
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy: lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo.
Ning SC; Hahn GM
Cancer Res; 1991 Nov; 51(21):5910-4. PubMed ID: 1718588
[TBL] [Abstract][Full Text] [Related]
19. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.
Teicher BA; Holden SA; Ara G; Northey D
Anticancer Res; 1993; 13(6A):2101-6. PubMed ID: 7507654
[TBL] [Abstract][Full Text] [Related]
20. CAI: effects on cytotoxic therapies in vitro and in vivo.
Teicher BA; Holden SA; Chen YN; Ara G; Korbut TT; Northey D
Cancer Chemother Pharmacol; 1994; 34(6):515-21. PubMed ID: 7923563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
